WO2002036172A3 - Rotavirus enterotoxin nsp4 and methods of using same - Google Patents

Rotavirus enterotoxin nsp4 and methods of using same Download PDF

Info

Publication number
WO2002036172A3
WO2002036172A3 PCT/US2001/045255 US0145255W WO0236172A3 WO 2002036172 A3 WO2002036172 A3 WO 2002036172A3 US 0145255 W US0145255 W US 0145255W WO 0236172 A3 WO0236172 A3 WO 0236172A3
Authority
WO
WIPO (PCT)
Prior art keywords
nsp4
methods
same
relates
rotavirus
Prior art date
Application number
PCT/US2001/045255
Other languages
French (fr)
Other versions
WO2002036172A2 (en
Inventor
Mary K Estes
Judith M Ball
Peng Tian
Original Assignee
Baylor College Medicine
Mary K Estes
Judith M Ball
Peng Tian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/705,621 external-priority patent/US6673355B1/en
Application filed by Baylor College Medicine, Mary K Estes, Judith M Ball, Peng Tian filed Critical Baylor College Medicine
Priority to EP01992588A priority Critical patent/EP1349571A4/en
Priority to CA002427809A priority patent/CA2427809A1/en
Priority to AU2002220025A priority patent/AU2002220025A1/en
Publication of WO2002036172A2 publication Critical patent/WO2002036172A2/en
Publication of WO2002036172A3 publication Critical patent/WO2002036172A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The rotavirus non-structural glycoprotein, NSP4, performs multiple functions in the virus replication cycle, especially during viral morphogenesis. Specifically, NSP4 is an intracellular receptor that mediates the acquisition of a transient membrane envelope during the budding of newly formed subviral particles into the endoplasmic reticulum (ER). The present invention relates to NSP4 and methods of use. More particularly, it relates to the use of NSP4 and fragments thereof (NSP4 114-135, NSP4 120-147, NSP4 112-174, or NSP4 112-150) as a prevention and/or treatment of rotaviral disease.
PCT/US2001/045255 2000-11-03 2001-11-02 Rotavirus enterotoxin nsp4 and methods of using same WO2002036172A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01992588A EP1349571A4 (en) 2000-11-03 2001-11-02 Rotavirus enterotoxin nsp4 and methods of using same
CA002427809A CA2427809A1 (en) 2000-11-03 2001-11-02 Rotavirus enterotoxin nsp4 and methods of using same
AU2002220025A AU2002220025A1 (en) 2000-11-03 2001-11-02 Rotavirus enterotoxin NSP4 and methods of using same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/705,621 2000-11-03
US09/705,621 US6673355B1 (en) 1995-06-14 2000-11-03 Rotavirus enterotoxin NSP4 and methods of using same

Publications (2)

Publication Number Publication Date
WO2002036172A2 WO2002036172A2 (en) 2002-05-10
WO2002036172A3 true WO2002036172A3 (en) 2002-09-19

Family

ID=24834264

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/045255 WO2002036172A2 (en) 2000-11-03 2001-11-02 Rotavirus enterotoxin nsp4 and methods of using same

Country Status (4)

Country Link
EP (1) EP1349571A4 (en)
AU (1) AU2002220025A1 (en)
CA (1) CA2427809A1 (en)
WO (1) WO2002036172A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1576877A1 (en) * 2004-03-04 2005-09-21 Bioprotein Technologies Preparation of recombinant rotavirus proteins in milk of transgenic non-human mammals
ES2514316T3 (en) 2005-11-22 2014-10-28 Novartis Vaccines And Diagnostics, Inc. Norovirus and Sapovirus virus-like particles (VLPs)
SI2814508T1 (en) * 2012-02-14 2017-10-30 Merial, Inc. Rotavirus subunit vaccines and methods of making and use thereof
US9585952B2 (en) 2012-05-16 2017-03-07 Adelaide Research & Innovation Pty Ltd Cellular vaccine and method of inducing an immune response in a subject
WO2016115630A1 (en) * 2015-01-23 2016-07-28 Medicago Inc. Rotavirus-like particle production in plants
CN108504718A (en) * 2018-03-27 2018-09-07 东莞市第三人民医院 A kind of CaSR is in the metainfective expression analysis method of RV, NSP4
CN117866858B (en) * 2023-11-30 2024-06-21 吉林农业大学 Recombinant Lactobacillus plantarum expressing porcine rotavirus antigen and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997000088A2 (en) * 1995-06-14 1997-01-03 Baylor College Of Medicine Rotavirus enterotoxin nsp4 and methods of using same
US5891676A (en) * 1986-12-30 1999-04-06 Baylor College Of Medicine Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298244A (en) * 1990-10-25 1994-03-29 University Of Saskatchewan Assembled viral particles and their use in a vaccine to rotaviral disease
US6534067B1 (en) * 1999-10-14 2003-03-18 Baylor College Of Medicine Rotavirus enterotoxin adjuvant
FR2806087B1 (en) * 2000-03-07 2002-10-18 Agronomique Inst Nat Rech PSEUDOVIRAL PARTICLES OF ROTAVIRUS AND THEIR USE FOR VECTORIZING PROTEINS OR NUCLEIC ACIDS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891676A (en) * 1986-12-30 1999-04-06 Baylor College Of Medicine Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system
WO1997000088A2 (en) * 1995-06-14 1997-01-03 Baylor College Of Medicine Rotavirus enterotoxin nsp4 and methods of using same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1349571A4 *

Also Published As

Publication number Publication date
EP1349571A2 (en) 2003-10-08
AU2002220025A1 (en) 2002-05-15
WO2002036172A2 (en) 2002-05-10
CA2427809A1 (en) 2002-05-10
EP1349571A4 (en) 2005-02-16

Similar Documents

Publication Publication Date Title
WO2004042001A3 (en) Virus-like particles, methods of preparation, and immonogenic compositions
WO2003077942A3 (en) Virus-like particles of human papillomavirus
WO2002028422A3 (en) Split enveloped virus preparation for intranasal delivery
WO2001089479A3 (en) Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds
WO2006085983A3 (en) Viral adjuvants
WO2002047607A3 (en) Process for the preparation of a fast dissolving dosage form
WO2002080884A3 (en) Powder inhaler formulations
WO2002018585A8 (en) Packaging of positive-strand rna virus replicon particles
RU2001101448A (en) EXTRACTS FROM ZANTHOXYLUM BUNGEANUM, PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM
WO2002028426A8 (en) Split enveloped virus preparation
GB0105877D0 (en) Use of flavivirus for the expression of protein epitopes and development of new live attenuated vaccine virus to immunize against flavivirus and otherinfecti
WO2003014079A8 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
WO2002036172A3 (en) Rotavirus enterotoxin nsp4 and methods of using same
ATE485833T1 (en) PHARMACEUTICAL COMPOSITIONS THAT PROMOTE THE IMMUNOGENICITY OF WEAKLY IMMUNOGENIC ANTIGENS
EP1238662A3 (en) Method for manufacturing drug granules, the drug granules and pharmaceutical preparation containing the drug granules
EP0652957A1 (en) Assembled viral particles and their use in a vaccine to rotaviral disease.
EP1420819A4 (en) Sub-unit vaccine for infectious pancreatic necrosis virus
MXPA02012249A (en) Peptides, compositions and methods for the treatment of burkholderia cepacia.
HUP0202233A3 (en) Derivatives and analogues of galanthamin, their use, pharmaceutical compositions containing them and process for the preparation of them
WO2006024240A3 (en) Vaccine composition against hepatitis c virus
WO2006114312A3 (en) Vaccine
MY135468A (en) Escitalopram hydrobromide and a method for the preparation thereof
WO2002072803A3 (en) Subgenomic replicons of the flavivirus dengue
WO2001097824A3 (en) Use of phyllanthus constituents for treating or preventing infections caused by flaviviridae
WO2004041853A3 (en) Hcv vaccine compositions comprising e1 and ns3 peptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2427809

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002220025

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001992588

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001992588

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001992588

Country of ref document: EP